Articles

Sequence Listing Requirements During PCT National Phase Entry

What Is the PCT National Phase and Why Does the Sequence Listing Matter?

When an international patent application filed under the Patent Cooperation Treaty (PCT) moves into individual countries or regions for further examination, this transition is called the national phase entry. For applicants working with biological inventions such as nucleotide or amino acid sequences, managing the sequence listing national phase requirements is one of the most critical steps in the entire patent prosecution process.

A sequence listing is a standardized document that discloses all biological sequences claimed or described in a patent application. If your PCT application contains sequences, then every national or regional patent office where you seek protection will expect this listing to meet specific format, language, and submission rules. Failing to meet these requirements can result in application rejection, additional fees, or missed deadlines that cannot be reversed.

This article is designed to educate inventors, patent attorneys, and IP professionals about the key requirements, common challenges, and practical steps involved in sequence listing national phase compliance.

Understanding the International Foundation: WIPO ST.26

Before entering the national phase, it is important to understand the international standard that governs sequence listings. The World Intellectual Property Organization (WIPO) introduced WIPO Standard ST.26 as the mandatory format for sequence listings in patent applications filed on or after July 1, 2022.

ST.26 replaced the older ST.25 standard, and this change has significant implications for sequence listing national phase filing. Under ST.26, sequence listings must be submitted as XML files rather than plain text files. This format is machine-readable, structured, and compatible with a range of automated validation tools provided by patent offices worldwide.

If your PCT application was filed before July 1, 2022, and therefore uses the ST.25 format, you will likely need to convert it to ST.26 format before or during national phase entry in many jurisdictions. This conversion is not automatic and must be carefully handled to avoid introducing errors or omissions.

Key facts about WIPO ST.26 you should know:

All sequences of nucleotides (DNA, RNA) and amino acids with 10 or more residues must be listed
The XML file must be generated using WIPO’s WIPO Sequence software or equivalent validated tools
The listing must be free-standing and self-contained, not embedded in the main description
Sequences must be assigned unique identifiers in a consistent numerical order
Non-disclosure of a sequence that should be listed can constitute an incomplete application

National Phase Entry: Country-Specific Requirements You Must Know

One of the most challenging aspects of sequence listing national phase compliance is that different patent offices have their own rules layered on top of the international ST.26 standard. While the format may be the same, the procedural requirements, deadlines, and language rules vary significantly by jurisdiction.

United States (USPTO)

The United States Patent and Trademark Office requires that a sequence listing compliant with ST.26 be submitted electronically through the Patent Center system. For national phase applications entering under 35 U.S.C. 371, the sequence listing must be submitted as part of the application on or before the national phase entry date, which is typically 30 months from the priority date.

If the sequence listing is not submitted by that date, applicants can still file it with a surcharge and a statement that the listing does not include any new matter beyond what was previously disclosed internationally. This statement is crucial and must be worded carefully.

European Patent Office (EPO)

The EPO requires sequence listings in ST.26 XML format and enforces strict rules about the language of the free-text qualifiers within the listing. The EPO accepts applications in English, French, and German, and the free-text portions of the sequence listing must match the language of the application. Any mismatch can trigger an objection during examination.

The EPO also requires that the sequence listing be submitted on the same day as the national phase entry request when entering via the EPC regional phase. Late submission may require filing a sequence listing correction request.

India (IPO)

The Indian Patent Office accepts ST.26 compliant XML sequence listings during national phase entry. India operates on a 31-month deadline from the priority date for national phase entry. The IPO has been gradually updating its infrastructure to handle XML-based ST.26 files, and applicants should verify current portal capabilities before filing.

China (CNIPA)

China’s National Intellectual Property Administration requires the sequence listing to be filed in both Chinese and the original language of the PCT application in some cases, depending on the nature of the free-text qualifiers. Sequence listing national phase filing in China often requires working with a local patent agent who understands both the technical and procedural requirements.

Japan (JPO)

Japan follows ST.26 requirements and allows submission of sequence listings in electronic form. Japanese practice requires that the sequence listing content align precisely with what was disclosed in the international application. Any discrepancy between the international publication and the national phase sequence listing can trigger an objection for added matter.

Common Mistakes and How to Avoid Them

Understanding the rules is only half the battle. In practice, many applicants and even experienced patent professionals make avoidable errors when handling the sequence listing national phase process. Here are the most frequently seen mistakes and how to prevent them:

Using outdated ST.25 format when ST.26 is required: Always verify the filing date of the PCT application and confirm which standard applies before preparing the national phase sequence listing.
Omitting sequences that should be listed: A sequence does not have to be claimed to be required in the listing. If it is disclosed in the description and meets the length threshold, it must appear in the sequence listing.
Incorrect organism names or qualifiers: The XML format in ST.26 includes structured fields for organism names, sequence types, and other qualifiers. Errors in these fields can lead to formal objections from the patent office.
Missing the national phase deadline with no sequence listing: Many offices treat the absence of a required sequence listing as a deficiency that triggers a grace period, but this period is short and comes with fees. Always plan to submit the sequence listing on the entry date.
Not requesting a sequence listing incorporation statement: In the USPTO, if the sequence listing was not part of the published international application, you must include a specific statement that the listing does not introduce new matter. Omitting this statement causes unnecessary delays.

Practical Steps for a Smooth Sequence Listing National Phase Entry

To ensure compliance and avoid costly errors, follow a structured approach when preparing for national phase entry in any jurisdiction.

First, review the international search report and the published PCT application to confirm all sequences are correctly disclosed and listed in the original filing. This is your baseline.

Second, determine whether your application falls under ST.25 or ST.26 depending on the filing date. If conversion is needed, use WIPO Sequence or work with a qualified sequence listing service provider to generate a validated XML file.

Third, check the specific requirements of each target country well in advance of the 30-month deadline. Some countries have additional language, content, or submission-portal requirements that need lead time to address.

Fourth, prepare a jurisdiction-by-jurisdiction checklist that includes the sequence listing format, required language, submission platform, deadline, and any associated fees. This organized approach prevents last-minute surprises.

Finally, always validate your ST.26 XML file using WIPO’s free validation tool before submission. This tool flags structural and content errors that would otherwise be caught only after filing, at greater cost and inconvenience.

Final Thoughts on Sequence Listing National Phase Compliance

The sequence listing national phase process sits at the intersection of scientific accuracy, legal precision, and procedural compliance. For any patent application involving biological sequences, getting this right is not optional. A well-prepared sequence listing that meets international and country-specific requirements protects your rights, avoids unnecessary office actions, and keeps your application moving forward efficiently.

Whether you are handling this in-house or working with a specialized service, understanding these requirements gives you the tools to make informed decisions. The sequence listing national phase landscape continues to evolve as patent offices complete their transition to ST.26, so staying current with official guidance from each office is equally important.

For inventors and businesses serious about protecting biological innovations globally, investing time and resources into proper sequence listing national phase preparation is one of the highest-value activities in the entire patent process.

We are the leading Patent Sequence Listing Company

At our Sequence Listing Company, we specialize exclusively in creating perfect patent sequence listings for biotechnology and pharmaceutical companies. Founded by patent attorneys and bioinformatics specialists with over 10 years of experience, we understand the critical intersection of scientific innovation and intellectual property protection. Our dedicated team has helped hundreds of companies successfully navigate the complex regulatory requirements of sequence listings across global patent offices. We combine technical precision with regulatory expertise to ensure your valuable innovations receive the protection they deserve without delays or complications.

Our Expertise

Specialized expertise in WIPO ST.25 and ST.26 standards
Customized solutions for complex biological sequences
Guaranteed compliance with patent office requirements
Rapid 24-48 hour turnaround time
Comprehensive quality assurance process

Trust Your Patent Sequence Listings to the Industry's Leading Experts

Effectual Knowledge Services pvt. ltd.

Effectual Services is an award-winning Intellectual Property (IP) management advisory & Consulting firm.